These specific branded products are FDA-approved for their indicated uses
doi: 10.18433/J3CC86 Summary Keywords type 2 diabetes mellitus, glucagon-like peptide-1 receptor agonists, gastrointestinal side effects, risk factors, nomogram Citation Gao R, Li Y, Li A, Zhou P, Zong H and Li Y (2024) Risk factor screening and prediction modeling of gastrointestinal adverse reactions caused by GLP-1RAs
This dual action of increasing insulin while decreasing glucagon creates a more balanced and effective approach to blood sugar control
In the same year, danuglipron, another small molecule oral GLP-1R agonist, also underwent phase two clinical trials
This suggests that the genetic risk score could offer a dual benefit: predicting both potential for side effects and likelihood of successful weight loss